Polymorphic markers associated with genes responsible for lipid and carbohydrate metabolism disorders and insulin resistance in cancer patients

Ulybina, Yu. M.; Imyanitov, Evgeny N.; Vasilyev, D. A.; Berstein, L M

doi:10.1134/s0026893308060034

Cited by 7 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the paper by Han et al [27] was excluded because it was a duplicated publication; the other paper by Terrasi et al [28] was also excluded because it was about the functional analysis of the LEP G2548A polymorphism in breast cancer cells. Therefore, 17 papers met the inclusion criteria: three studies for LEP G2548A polymorphism [7][8][9], nine studies for LEPR Q223R polymorphism [7][8][9][10][11][12][13][14][15], five studies for LEPR Lys109Arg polymorphism [8,10,[14][15][16], four studies for PON1 L55M polymorphism, and five studies for PON1 Q192R polymorphism. A flow chart summarizing the process of study inclusion/exclusion was depicted in Fig.…”

Section: Characteristics Of Primary Studiesmentioning

confidence: 99%

“…1. Of these studies, all three were on Caucasians [7][8][9] for LEP G2548A polymorphism; five were on Caucasians [7-9, 11, 14], two were on Asians [10,12], one was on Africans [13], and one was on mixed population [15] for LEPR Q223R polymorphism; two were on Caucasians [8,14], two were on Asians [10,16], and one was on mixed population [15] for LEPR Lys109Arg polymorphism; two were on Caucasians [20,22], one was on Asians [21], and one was on mixed population [19] for PON1 L55M polymorphism; and three were on Caucasians [11,20,22], one was on Asians [21], and one was on mixed population [19] for PON1 Q192R polymorphism. The characteristics of the included studies are listed in Table 1.…”

Section: Characteristics Of Primary Studiesmentioning

confidence: 99%

“…Recently, several studies have investigated the associations of several polymorphisms in LEP and LEPR genes with breast cancer risk. Of these polymorphisms, three have been most commonly studied: LEP G2548A (rs7799039) [7][8][9], LEPR Q223R (rs1137101) [7][8][9][10][11][12][13][14][15], and Lys109Arg (rs1137100) [8,10,[14][15][16]. However, the results were inconsistent.…”

Section: Introductionmentioning

confidence: 95%

See 2 more Smart Citations

Polymorphisms in three obesity-related genes (LEP, LEPR, and PON1) and breast cancer risk: a meta-analysis

Liu

2011

Tumor Biol.

View full text Add to dashboard Cite

Common genetic variations in the leptin (LEP), leptin receptor (LEPR), and paraoxonase 1 (PON1) genes have been considered to be implicated in the development of breast cancer. However, the results were inconsistent. In this study, a meta-analysis was performed to assess the associations of five polymorphisms, including LEP G2548A, LEPR Q223R, LEPR Lys109Arg, PON1 L55M, and PON1 Q192R polymorphisms, with breast cancer risk. Published literature from PubMed, ISI Web of Science, Embase databases, CNKI, and Wanfang Data were retrieved. All studies evaluating the association between LEP G2548A, LEPR Q223R, LEPR Lys109Arg, PON1 L55M, or PON1 Q192R polymorphism and breast cancer risk were included. Pooled odds ratio (OR) with 95% confidence interval (CI) was calculated using fixed- or random-effects model. Three studies (2,003 cases and 1,967 controls) for LEP G2548A polymorphism, nine studies (4,627 cases and 5,476 controls) for LEPR Q223R polymorphism, five studies (2,759 cases and 2,573 controls) for LEPR Lys109Arg polymorphism, four studies (1,517 cases and 1,379 controls) for PON1 L55M polymorphism, and five studies (1,575 cases and 2,283 controls) for PON1 Q192R polymorphism were included in the meta-analysis. Overall, the results showed null significant association between LEP G2548A, LEPR Q223R, LEPR Lys109Arg, or PON1 Q192R polymorphism and breast cancer risk; however, PON1 L55M was significantly associated with breast cancer risk overall (MM vs. LL: OR = 2.16; 95% CI, 1.76-2.66). For LEPR Q223R polymorphism, further subgroup analysis suggested that the association was only statistically significant in East Asians (OR = 0.50; 95% CI, 0.36-0.70) but not in Caucasians (OR = 1.06; 95% CI, 0.77-1.45) or Africans (OR = 1.30; 95% CI, 0.83-2.03). The present meta-analysis suggested that LEPR Q223R polymorphism might be implicated in the development of breast cancer in East Asians; PON1 L55M might increase breast cancer risk. However, given the limited sample size, the findings warrant further investigation.

show abstract

Section: Characteristics Of Primary Studiesmentioning

confidence: 99%

Section: Characteristics Of Primary Studiesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

Polymorphisms in three obesity-related genes (LEP, LEPR, and PON1) and breast cancer risk: a meta-analysis

Liu

2011

Tumor Biol.

View full text Add to dashboard Cite

show abstract

“…Another study 34 was excluded because it was review article, one studies 37 were excluded because it was a case-only study, two studies 38,39 were excluded they were not case-control studies. Ultimately, 21 studies 8–28 were included in this meta-analysis. Their characteristics and genotype distributions are summarized in Table 1.…”

Section: Resultsmentioning

confidence: 99%

Correlation of Q223R and K109R polymorphisms in leptin receptor gene with susceptibility of breast cancer: A systematic review and meta-analysis

Zhu

Zhong

Tang

et al. 2023

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

Background: Increasing evidence has suggested a strong association of Q223R (rs1137101) and K109R (rs1137100) polymorphisms in leptin receptor (LEPR) gene with susceptibility of breast cancer (BC), but inconsistent results were obtained. To provide a quantitative assessment of this association, a systematic review and meta-analysis was performed. Methods: A literature search of PubMed, EMBASE, Google Scholar, and the Chinese National Knowledge Infrastructure was collected. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated. Results: A total of 20 case-control studies for Q223R polymorphism and 8 case-control studies for K109R polymorphism were included. Significant association between Q223R polymorphism and BC risk was not found in total, Asian or Caucasian population, but

show abstract

“…STK11/LKB1 (rs8111699), и гена C11orf65 (rs11212617), локализующегося в том же локусе, что и ген атаксии-телеангиэктазии, ATM [8,11,12]. Вторую группу соста-вили полиморфные варианты генов рецепторов лептина, LEPR_Gln223Arg (rs1137101), половые гормоны связыва-ющего глобулина, SHBG_D356N (rs6259) и 8-оксигуанин-ДНК-гликозилазы, OGG1Ser326Cys (rs1052134), а также полиморфизм локуса rs11065987, локализующегося вблизи гена BRAP, связанного с онкосупрессором BRCA1 и модулирующего рост и дифференцировку клеток и функционирование провоспалительных сигнальных путей [13][14][15][16].…”

Section: материалы и методыunclassified

Hormonal, metabolic and genetic predictors of metformin efficacy in patients with diabetes mellitus and cancer

Bershteyn¹,

Васильев²,

Иевлева³

et al. 2014

Diabetes mellitus

View full text Add to dashboard Cite

Aims. To compare hormonal and metabolic profile of type 2 diabetes mellitus patients (T2DM) with or without neoplastic processes with the data from screening for SNPs affecting sensitivity to metformin.To compare the abovementioned parameters including relevant genotype frequency in patients with positive and negative response to metformin.Materials and Methods. A total of 167 patients, all female, aged 43 to 88 years in menopause no shorter than 1 year, with or without history of T2DM were enrolled in this study. 156 patients underwent genetic screening for SNPs that were previously suggested as relevant to metformin efficacy. 55 patients received metformin 1000-1700 g daily with hormonal and metabolic monitoring and assessment of surrogate antineoplastic markers (such as endometrial thickness and mammographic density of mammary glands). Results. There was no unifying hormonal or metabolic phenotype for patients with given metformin-associated SNPs. However, we observed a certain trend for alterations in HOMA-IR and plasma estradiol levels. Dyslipidemia and elevated estradiol levels were positively associated with both types of positive response to metformin ? ?metabolic? and ?antineoplastic? ? though the latter was observed less frequently. Our data suggests that among 8 studied SNPs, the OCT1_R61C genotype (organic cation transporter-1) carriers require more close attention. Conclusion. Larger studies are required for further elucidation of the genetic background for metformin action in patients with various forms of cancer.

show abstract

Polymorphic markers associated with genes responsible for lipid and carbohydrate metabolism disorders and insulin resistance in cancer patients

Cited by 7 publications

References 33 publications

Polymorphisms in three obesity-related genes (LEP, LEPR, and PON1) and breast cancer risk: a meta-analysis

Polymorphisms in three obesity-related genes (LEP, LEPR, and PON1) and breast cancer risk: a meta-analysis

Correlation of Q223R and K109R polymorphisms in leptin receptor gene with susceptibility of breast cancer: A systematic review and meta-analysis

Hormonal, metabolic and genetic predictors of metformin efficacy in patients with diabetes mellitus and cancer

Contact Info

Product

Resources

About